Skip to main content
. 2020 Apr 28;12(5):1095. doi: 10.3390/cancers12051095

Figure 5.

Figure 5

Effect of VE-821 and olaparib combination on cell cycle and homologous recombination repair (HRR). (A) Cell cycle analysis of SHSY5Y, SKNAS and NGP cell lines treated with 5 µM (SHSY5Y and SKNAS) or 1 µM (NGP) olaparib in combination with 1 μM VE-821 for 24 h. Data are mean + SEM from 3 independent experiments. (B) Representative γH2AX and Rad51 foci images from SKNAS and NGP cell lines treated with 1 µM VE-821, 10 µM olaparib or both for 24 h. (C) Average number of Rad51 foci per cell for NGP, N20_R1, SHSY5Y and SKNAS cell lines treated with 1 µM VE-821, 10 µM olaparib or both, n = 4 + sd. (D) Average γH2AX nuclear fluorescence intensity for NGP, N20_R1, SHSY5Y and SKNAS cell lines treated with 1 µM VE-821, 10 µM olaparib or both, fold change from control (DMSO), data are mean + SEM from 4 independent experiments. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, 2-way ANOVA difference from control (DMSO).